StockNews.com Initiates Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Stock analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.55 on Friday. The firm has a 50-day moving average of $0.55 and a 200-day moving average of $0.60. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $1.97. The company has a market cap of $30.32 million, a P/E ratio of -0.22 and a beta of 1.03.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. increased its position in shares of Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 126,752 shares during the last quarter. Franklin Resources Inc. grew its stake in Marinus Pharmaceuticals by 34.9% in the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares during the period. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in shares of Marinus Pharmaceuticals during the 4th quarter worth $54,000. Finally, Deltec Asset Management LLC purchased a new position in shares of Marinus Pharmaceuticals in the 4th quarter worth about $107,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.